Is buying CSL shares right now a smart move?

Experts are tipping a strong recovery for the healthcare stock.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • The CSL share price could be about to embark on a green streak if bullish experts are to be believed
  • The stock is still trading around 20% below its pre-pandemic highs
  • But one expert thinks that, if all goes well for the stock, it could rocket beyond its previous record high

The CSL Limited (ASX: CSL) share price still hasn't recovered to its pre-pandemic level, which saw it trading solidly above the $300 mark.

Indeed, the S&P/ASX 200 Index (ASX: XJO) healthcare stock is nearly 20% lower than the record high of $342.75 it posted in February 2020.

Could things be about to turn around for the CSL share price? Some experts are tipping it to do big things from here.

Right now, the CSL share price is $275.98.

A scientist examining test results.

Image source: Getty Images

Is now a good time to buy CSL shares?

It's been a rough couple of years for the CSL share price despite plenty of exciting happenings at the company.

Most obviously, it completed its $16 billion acquisition of Swiss giant Vifor Pharma earlier this year.

The ASX-listed healthcare favourite also recently revealed that, Vifor Pharma's contribution included, it expects to post between US$2.7 billion and US$2.8 billion of net profit before tax and amortisation for financial year 2023.

The team at Morgans was pleased by the news, retaining its buy rating and adjusting its price target for CSL shares to $312.20, my Fool colleague James reports. That represents a potential 13% upside.

The broker said strong plasma collections and demand, as well as the addition of Vifor Pharma, "portends strong growth momentum".

Meanwhile, Goldman Sachs remained neutral on the stock following its most recent announcement, tipping it to lift to $291 – a potential 5% gain.

Tribeca Investment Partners portfolio manager Jun Bei Liu is also hopeful about the stock. She said it was one of numerous in the space trading at a reasonable valuation, saying, courtesy of Livewire:

We do think healthcare will perform very well in an uncertain environment. These companies will deliver very strong earnings growth regardless of the economic outlook.

But the most bullish expert is Fairmont Equities founder Michael Gable. My Fool colleague Tony quoted the expert as telling media:

In some ways, CSL might have dropped off people's radar because since the COVID lows [the share price] hasn't really done anything.

It bottomed in February… and now it's starting to outperform the broader index.

You could see CSL with a four in front of it potentially by the end of next year, if it breaks out.

To reach the $400 mark, the CSL share price would have to gain around 45%. No doubt plenty of investors will have their fingers crossed for such a rise.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. and Goldman Sachs. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A white and black clock face is shown with three hands saying Time to Buy reflecting Citi's view that it's time to buy ASX 200 banks
Broker Notes

3 reasons to buy Pro Medicus shares today

Two leading investment analysts believe Pro Medicus shares are primed for a rebound.

Read more »

Middle age caucasian man smiling confident drinking coffee at home.
Healthcare Shares

Should I invest $10,000 into CSL shares? Yes or no

Is it time to pick up this fallen giant? Let's dig deeper into things.

Read more »

A woman scratches her head, thinking is this a no-brainer?
Healthcare Shares

Does this ASX 200 stock's fall make it a no-brainer buy?

Despite a major transformation, this stock is down more than 20%. Is this an opportunity?

Read more »

Scientist looking at a laptop thinking about the share price performance.
Healthcare Shares

ASX 200 healthcare shares down 33% in a year as heavyweights hit multi-year lows

Eight of the 10 largest healthcare shares are trading at or close to multi-year or 52-week lows.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Healthcare Shares

Up 2,075% in a year, why is the 4DMedical share price rocketing again on Friday?

Investors just sent 4DMedical shares surging another 20% on Friday. But why?

Read more »

Businessman working and using Digital Tablet new business project finance investment at coffee cafe.
Healthcare Shares

Buy, hold, sell: What is Ord Minnett saying about this popular ASX 200 stock?

Here's what the broker is saying about this stock.

Read more »

A man in a shirt and tie looks to the horizon holding his hand above his eyes as if to shield the sun so he can see better.
Healthcare Shares

Why is everyone talking about 4DX shares this week?

It's all eyes on the healthcare stock this week.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face.
Healthcare Shares

$10,000 invested in this ASX healthcare share a year ago is now worth $36,500

This stock has experienced a dramatic price increase.

Read more »